NeuroSense Collaborates With Lonza To Identify Exosome-Based Biomarkers For Advance Neurodegenerative Disease Treatments And Diagnostics
NeuroSense Collaborates With Lonza To Identify Exosome-Based Biomarkers For Advance Neurodegenerative Disease Treatments And Diagnostics
NeuroSense 與 Lonza 合作識別基於外泌體的生物標誌物，用於先進的神經退行性疾病治療和診斷
- NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field
- Lonza to develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes ("NDEs"), set to be integrated into the clinical development program of PrimeC by NeuroSense
- Lonza's Dev-on-Demand solution to enable NeuroSense to access Lonza's process development with rapid initiation, execution, and delivery of work
- NeuroSense將利用其在生物標誌物利用方面的豐富經驗來推進神經變性領域的早期診斷和治療
- Lonza將開發、優化和鑑定一種利用神經元衍生外泌體（“NDE”）的方法，該方法將整合到NeuroSense的PrimeC臨床開發計劃中
- Lonza 的按需開發解決方案使 NeuroSense 能夠通過快速啓動、執行和交付工作來訪問 Lonza 的流程開發
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。